Development of a comprehensive cardiac atlas on a 1.5 Tesla Magnetic Resonance Linear Accelerator.

Autor:	Schottstaedt AM; Medical College of Wisconsin, Department of Radiation Oncology, Milwaukee, WI, United States., Paulson ES; Medical College of Wisconsin, Department of Radiation Oncology, Milwaukee, WI, United States.; Medical College of Wisconsin, Department of Radiology, Milwaukee, WI, United States., Rubenstein JC; Medical College of Wisconsin, Department of Radiology, Milwaukee, WI, United States.; Medical College of Wisconsin, Department of Cardiology, Milwaukee, WI, United States., Chen X; Medical College of Wisconsin, Department of Radiation Oncology, Milwaukee, WI, United States., Omari EA; Medical College of Wisconsin, Department of Radiation Oncology, Milwaukee, WI, United States., Li XA; Medical College of Wisconsin, Department of Radiation Oncology, Milwaukee, WI, United States., Schultz CJ; Medical College of Wisconsin, Department of Radiation Oncology, Milwaukee, WI, United States., Puckett LL; Medical College of Wisconsin, Department of Radiation Oncology, Milwaukee, WI, United States., Robinson CG; Washington University, Department of Radiation Oncology, St. Louis, MO, United States., Alongi F; IRCCS Sacro Cuore Don Calabria Hospital, Department of Radiation Oncology, Negrar-Verona, Italy & University of Brescia, Faculty of Medicine, Brescia, Italy., Gore EM; Medical College of Wisconsin, Department of Radiation Oncology, Milwaukee, WI, United States., Hall WA; Medical College of Wisconsin, Department of Radiation Oncology, Milwaukee, WI, United States.
Jazyk:	angličtina
Zdroj:	Physics and imaging in radiation oncology [Phys Imaging Radiat Oncol] 2023 Nov 07; Vol. 28, pp. 100504. Date of Electronic Publication: 2023 Nov 07 (Print Publication: 2023).
DOI:	10.1016/j.phro.2023.100504
Abstrakt:	Background and Purpose: The 1.5 Tesla (T) Magnetic Resonance Linear Accelerator (MRL) provides an innovative modality for improved cardiac imaging when planning radiation treatment. No MRL based cardiac atlases currently exist, thus, we sought to comprehensively characterize cardiac substructures, including the conduction system, from cardiac images acquired using a 1.5 T MRL and provide contouring guidelines. Materials and Methods: Five volunteers were enrolled in a prospective protocol (NCT03500081) and were imaged on the 1.5 T MRL with Half Fourier Single-Shot Turbo Spin-Echo (HASTE) and 3D Balanced Steady-State Free Precession (bSSFP) sequences in axial, short axis, and vertical long axis. Cardiac anatomy was contoured by (AS) and confirmed by a board certified cardiologist (JR) with expertise in cardiac MR imaging. Results: A total of five volunteers had images acquired with the HASTE sequence, with 21 contours created on each image. One of these volunteers had additional images obtained with 3D bSSFP sequences in the axial plane and additional images obtained with HASTE sequences in the key cardiac planes. Contouring guidelines were created and outlined. 15-16 contours were made for the short axis and vertical long axis. The cardiac conduction system was demonstrated with eleven representative contours. There was reasonable variation of contour volume across volunteers, with structures more clearly delineated on the 3D bSSFP sequence. Conclusions: We present a comprehensive cardiac atlas using novel images acquired prospectively on a 1.5 T MRL. This cardiac atlas provides a novel resource for radiation oncologists in delineating cardiac structures for treatment with radiotherapy, with special focus on the cardiac conduction system. Competing Interests: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: X Allen Li: Grant/contracts – NIH/NCI, Elekta AB, Siemens; Honorarium – Accuray Inc; Support for meeting – Elekta AB. Fillipo Alongi: Grant/contracts, consulting fees, payment/honorarium, and meeting support – Elekta. Erick Paulson: Grant: Elekta, Siemens; Software licenses – Philips. Christopher Schultz: Grants/Contracts – MRL Consortium; Support for meeting – Elekta. Clifford Robinson: Grants – Varian, Merck; Consulting fees – Varian, radialogica, AstraZeneca, EMD Serono; Stock – Radialogica. Lindsay L. Puckett: Payment/honoraria and support for meeting – Accuray. William Hall: Support for meeting – Elekta. Xinfeng Chen: None. Eenas Omari: None. Elizabeth Gore: None. Aronne Schottstaedt: None. (© 2023 The Author(s).)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu